Skip to main content

Advertisement

SpringerLink
Log in

Locally advanced non-small cell lung cancer

  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Locally advanced non-small cell lung cancer remains a paradoxical entity to manage. Although this type of cancer is confined to the thorax and is ostensibly curable, most patients presenting at this stage of disease eventually succumb to it. The accepted therapy presently includes chemotherapy and radiation. The exact agents, schedules, and combinations need to be defined further, although cisplatin has become the widely viewed standard cytotoxic drug in this setting. Notwithstanding, newer chemo-therapeutic and biologic agents are being extensively tested to find less toxic options with greater efficacy. Drugs that are gaining widespread approval include carboplatin, paclitaxel, gemcitabine, and vinorelbine. At the same time, advances in radiation therapy are triggering a revolution in dose intensity and scheduling that will one day offer superlative local control.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Greenlee RT, Murray T, Bolden S, Wingo PA: Cancer statistics, 2000. CA Cancer J Clin 2000, 50:7–33.

    Article  PubMed  CAS  Google Scholar 

  2. Ginsberg R, Vokes E, Raben A: Non-small cell lung cancer. In Cancer: Principles & Practice of Oncology. Edited by DeVita VT, Hellman S, Rosenberg SA. Philadelphia: Lippincott-Raven; 1997:858–911.

    Google Scholar 

  3. Perez CA, Pajak TF, Rubin P, et al.: Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group. Cancer 1987, 59:1874–1881.

    Article  PubMed  CAS  Google Scholar 

  4. Dillman RO, Seagren SL, Propert KJ, et al.: A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer [see comments]. N Engl J Med 1990, 323:940–945.

    Article  PubMed  CAS  Google Scholar 

  5. Dillman RO, Herndon J, Seagren SL, et al.: Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial [see comments]. J Natl Cancer Inst 1996, 88:1210–1215.

    Article  PubMed  CAS  Google Scholar 

  6. Le Chevalier T, Arriagada R, Quoix E, et al.: Radiotherapy alone versus combined chemotherapy and radio-therapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 1991, 83:417–423.

    Article  PubMed  Google Scholar 

  7. Arriagada R, Le Chevalier T, Rekacewicz C, Tarayre M: Cisplatin-based chemotherapy in patients with locally advanced non-small cell lung cancer: late analysis of a French randomized trial. Am Soc Clin Oncol 1997, 16.

  8. Morton RF, Jett JR, McGinnis WL, et al.: Thoracic radiation therapy alone compared with combined chemo-radiotherapy for locally unresectable non-small cell lung cancer. A randomized, phase III trial. Ann Intern Med 1991, 115:681–686.

    PubMed  CAS  Google Scholar 

  9. Crino L, Latini P, Meacci M, et al.: Induction chemotherapy plus high-dose radiotherapy versus radiotherapy alone in locally advanced unresectable non-small-cell lung cancer. Ann Oncol 1993, 4:847–851.

    PubMed  CAS  Google Scholar 

  10. Planting A, Helle P, Drings P, et al.: A randomized study of high-dose split course radiotherapy preceded by high-dose chemotherapy versus high-dose radiotherapy only in locally advanced non-small-cell lung cancer. An EORTC Lung Cancer Cooperative Group trial. Ann Oncol 1996, 7:139–144.

    PubMed  CAS  Google Scholar 

  11. Schaake-Koning C, van den Bogaert W, Dalesio O, et al.:Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer [see comments]. N Engl J Med 1992, 326:524–530.

    Article  PubMed  CAS  Google Scholar 

  12. Blanke C, Ansari R, Mantravadi R, et al.: Phase III trial of thoracic irradiation with or without cisplatin for locally advanced unresectable non-small-cell lung cancer: a Hoosier Oncology Group protocol. J Clin Oncol 1995, 13:1425–1429.

    PubMed  CAS  Google Scholar 

  13. Soresi E, Clerici M, Grilli R, et al.: A randomized clinical trial comparing radiation therapy v radiation therapy plus cis-dichlorodiammine platinum (II) in the treat-ment of locally advanced non-small cell lung cancer. Semin Oncol 1988, 15:20–25.

    PubMed  CAS  Google Scholar 

  14. Trovo MG, Minatel E, Franchin G, et al.: Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non-small cell lung cancer [see comments]. Int J Radiat Oncol Biol Phys 1992, 24:11–15.

    PubMed  CAS  Google Scholar 

  15. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995, 311: 899–909.

    Google Scholar 

  16. Marino P, Preatoni A, Cantoni A: Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer. A meta-analysis. Cancer 1995, 76:593–601.

    Article  PubMed  CAS  Google Scholar 

  17. Pritchard RS, Anthony SP: Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer. A meta-analysis. Ann Intern Med 1996, 125:723–729.

    PubMed  CAS  Google Scholar 

  18. Furuse K, Fukuoka M, Kawahara M, et al.: Phase III study of concurrent versus sequential thoracic radio-therapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999, 17:2692–2699. A large, well conducted, phase III trial comparing sequential to concurrent chemoradiation showing a benefit to the latter strategy.

    PubMed  CAS  Google Scholar 

  19. Sause WT, Scott C, Taylor S, et al.: Phase II trial of combination chemotherapy and irradiation in non-small-cell lung cancer, Radiation Therapy Oncology Group 88–04. Am J Clin Oncol 1992, 15:163–167.

    Article  PubMed  CAS  Google Scholar 

  20. Ardizzoni A, Grossi F, Scolaro T, et al.: Induction chemotherapy followed by concurrent standard radiotherapy and daily low-dose cisplatin in locally advanced non-small-cell lung cancer. Br J Cancer 1999, 81:310–315.

    Article  PubMed  CAS  Google Scholar 

  21. Pujol JL, Lafontaine T, Quantin X, et al.: Neoadjuvant etoposide, ifosfamide, and cisplatin followed by concomitant thoracic radiotherapy and continuous cisplatin infusion in stage IIIb non-small cell lung cancer. Chest 1999, 115:144–150.

    Article  PubMed  CAS  Google Scholar 

  22. Dowell J, Carbone D, Kavanaugh D, Rosenthal D: A phase I study of seven-week continuous infusion paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer. Am Soc Clin Oncol 1999, 18.

  23. Lau DH, Ryu JK, Gandara DR, et al.: Twice-weekly paclitaxel and radiation for stage III non-small cell lung cancer. Semin Oncol 1997, 24:S12–106–S12–109.

    Google Scholar 

  24. Kirkbride P, Gelmon K, Eisenhauer E, et al.: A phase I/II study of paclitaxel (TAXOL) and concurrent radiother-apy in advanced nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys 1997, 39:1107 - 1111.

    Article  PubMed  CAS  Google Scholar 

  25. Choy H, Safran H, Akerley W, et al.: Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer. Clin Cancer Res 1998, 4:1931–1936.

    PubMed  CAS  Google Scholar 

  26. Wolf M, Faoro C, Goerg C, et al.: Paclitaxel and simulta-neous radiation in the treatment of stage IIIA/B non-small cell lung cancer. Semin Oncol 1996, 23:108–112.

    PubMed  CAS  Google Scholar 

  27. Wagner H, Antonia S, Williams C, et al.: Concurrent paclitaxel/cisplatin with thoracic radiation in patients with stage IIIA/B non-small cell lung cancer. Am Soc Clin Oncol 1997, 16.

  28. Greco FA, Stroup SL, Gray JR, Hainsworth JD: Paclitaxel in combination chemotherapy with radiotherapy in patients with unresectable stage III non-small-cell lung cancer. J Clin Oncol 1996, 14:1642–1648.

    PubMed  CAS  Google Scholar 

  29. Atagi S, Kawahara M, Ogawara M, et al.: Phase II trial of daily low-dose carboplatin and thoracic radiother-apy in elderly patients with locally advanced non-small cell lung cancer. Jpn J Clin Oncol 2000, 30:59–64.

    Article  PubMed  CAS  Google Scholar 

  30. Satoh H, Ohara K, Fuji H, et al.: Use of daily low-dose carboplatin in radiotherapy for non-small cell lung cancer. Anticancer Res 1998, 18:4625–4627.

    PubMed  CAS  Google Scholar 

  31. Lau DH, Crowley JJ, Gandara DR, et al.: Southwest Oncology Group phase II trial of concurrent carbo-platin, etoposide, and radiation for poor-risk stage III non-small-cell lung cancer. J Clin Oncol 1998, 16:3078–3081.

    PubMed  CAS  Google Scholar 

  32. Choy H, Akerley W, Safran H, et al.: Multiinstitutional phase II trial of paclitaxel, carboplatin, and concur-rent radiation therapy for locally advanced non-small-cell lung cancer. J Clin Oncol 1998, 16:3316–3322.

    PubMed  CAS  Google Scholar 

  33. Bhatia S, Sandler A, Pletcher W, Einhorn L: Phase 2 study of paclitaxel, carboplatin and radiation therapy for locally advanced or inoperable non small cell lung cancer: a Hoosier Oncology Group trial. Proc ASCO 1999, 18:1847.

    Google Scholar 

  34. Belani C, Aisner J, Day R, Hiponia D: Weekly paclitaxel and carboplatin with simultaneous thoracic radio-therapy for locally advanced non-small cell lung cancer: three year follow-up. Proc ASCO 1997, 16:1608.

    Google Scholar 

  35. Langer CJ, Movsas B, Hudes R, et al.: Induction pacli-taxel and carboplatin followed by concurrent chemo-radiotherapy in patients with unresectable, locally advanced non-small cell lung carcinoma: report of Fox Chase Cancer Center study 94=2-001. Semin Oncol 1997, 24:S12–89–S12–95.

    Google Scholar 

  36. Clamon G, Herndon J, Cooper R, et al.: Radiosensitiza-tion with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. J Clin Oncol 1999, 17:4–11.

    PubMed  CAS  Google Scholar 

  37. Tsukada H, Moriyama H, Yokoyama A, Kurita Y:A phase II trial of individualized response-based induction chemotherapy of mitomycin-C, vindesine, cisplatin followed by thoracic radiotherapy with low-dose carboplatin for the treatment of unresectable stage III non-small cell lung cancer. Proc ASCO 1999, 18:2024.

    Google Scholar 

  38. Davis M, Kuebler P, Pedrick T, Wheeler W: Phase II trial of combined modality therapy for stage IIIa and IIIb nonsmall cell lung cancer. Proc ASCO 1999, 18:1931.

    Google Scholar 

  39. Cohen E, Hoffman P, Masters G, et al.: Phase I study of carboplatin and vinorelbine with concomitant radiation therapy in advanced non-small cell lung cancer. Ninth World Conference on Lung Cancer 2000, 29:346.

    Google Scholar 

  40. Sistermanns J, Hoffmanns H: Phase II study of docetaxel with simultaneous radiochemotherapy in patients with locally advanced non-resectable non-small cell lung cancer-preliminary results. Proc ASCO 1999, 18:2014.

    Google Scholar 

  41. Steina A, Ingvil H, Reidul H: Docetaxel with concurrent radiation in locally advanced non-small cell lung cancer. Proc ASCO 1999,18:1850.

    Google Scholar 

  42. Koukourakis MI, Bahlitzanakis N, Froudarakis M, et al.:Concurrent conventionally factionated radiotherapy and weekly docetaxel in the treatment of stage IIIb non-small-cell lung carcinoma. Br J Cancer 1999, 80:1792–1796.

    Article  PubMed  CAS  Google Scholar 

  43. Mauer AM, Masters GA, Haraf DJ, et al.: Phase I study of docetaxel with concomitant thoracic radiation therapy. J Clin Oncol 1998, 16:159–164.

    PubMed  CAS  Google Scholar 

  44. Nyman J, Mercke C: Docetaxel and cisplatin as induction and concomitant chemotherapy combined with accelerated radiotherapy for stage III non-small cell lung cancer—a Phase II study. Proc ASCO 1999, 18:1998.

    Google Scholar 

  45. Gandara D, Lovato L, Albain K, Livingston R: Pathologic stage IIIb non-small cell lung cancer: prolonged survival with consolidation docetaxel following concurrent chemoradiotherapy. Ninth World Conference on Lung Cancer 2000, 29:302.

    Google Scholar 

  46. Masters GA, Haraf DJ, Hoffman PC, et al.: Phase I study of vinorelbine, cisplatin, and concomitant thoracic radiation in the treatment of advanced chest malig-nancies. J Clin Oncol 1998, 16:2157–2163.

    PubMed  CAS  Google Scholar 

  47. Blackstock A, Richards F, Lovelace J, et al.: Twice-weekly gemcitabine and concurrent thoracic radiotherapy—a phase I/II study in patients with advanced non-small cell lung cancer. Proc ASCO 1999, 18:1918.

    Google Scholar 

  48. Scalliet P, Goor C, Turrisi A: Gemcitabine with thoracic radiotherapy—a phase II pilot study in chemonaive patients with advanced non-small cell lung cancer. Proc ASCO 1998, 17:1923.

    Google Scholar 

  49. Zinner R, Fossella F, Komaki R, Hong W: Phase I trial of concurrent gemcitabine plus chest radiotherapy, followed by consolidation systemic chemotherapy with gemcitabine plus cisplatin, for patients with stage III and medically inoperable stage II non-small cell lung cancer. Proc ASCO 1999, 18:1798.

    Google Scholar 

  50. Mauer A, Haraf D, Rudin C, Vokes E: A phase I/II study of induction irinotecan, paclitaxel, and carboplatin followed by concurrent thoracic radiotherapy with irino-tecan, paclitaxel, and carboplatin in unresectable, locally advanced non-small cell lung cancer. Ninth World Conference on Lung Cancer 2000, 29:376.

    Google Scholar 

  51. Fukada M, Fukada M, Soda H, et al.: Phase I study of irinotecan and cisplatin with concurrent thoracic radiotherapy in locally advanced non-small cell lung cancer. Proc ASCO 1999, 18:1796.

    Google Scholar 

  52. Takeda K, Negoro S, Kudoh S, et al.: Phase I/II study of weekly irinotecan and concurrent radiation therapy for locally advanced non-small cell lung cancer. Br J Cancer 1999, 79:1462–1467.

    Article  PubMed  CAS  Google Scholar 

  53. Vokes E, Leopold K, Herndon J, et al.: CALGB study 9431: a randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy and concomitant chemoradiotherapy for unresectable stage III non-small cell lung cancer. Ninth World Conference on Lung Cancer 2000, 29:158.

    Google Scholar 

  54. Cox JD, Azarnia N, Byhardt RW, et al.: A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83–11. J Clin Oncol 1990, 8:1543–1555.

    PubMed  CAS  Google Scholar 

  55. Cox JD, Pajak TF, Asbell S, et al.: Interruptions of high-dose radiation therapy decrease long-term survival of favorable patients with unresectable non-small cell carcinoma of the lung: analysis of 1244 cases from 3 Radiation Therapy Oncology Group (RTOG) trials. Int J Radiat Oncol Biol Phys 1993, 27:493–498.

    PubMed  CAS  Google Scholar 

  56. Saunders MI, Dische S: Continuous, hyperfractionated, accelerated radiotherapy (CHART) in non-small cell carcinoma of the bronchus. Int J Radiat Oncol Biol Phys 1990, 19:1211–1215.

    PubMed  CAS  Google Scholar 

  57. Saunders M, Dische S, Barrett A, et al.: Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multi-centre trial. CHART Steering committee. Radiother Oncol 1999, 52:137–148. The trial that established CHART as more effective than standard RT. These findings led the Royal College of Radiologists in Britain to recommend CHART in all eligible patients.

    Article  PubMed  CAS  Google Scholar 

  58. Saunders M, Dische S, Barrett A, et al.: Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee. Lancet 1997, 350:161–165.

    Article  PubMed  CAS  Google Scholar 

  59. Bailey AJ, Parmar MK, Stephens RJ: Patient-reported short-term and long-term physical and psychologic symptoms: results of the continuous hyperfraction-ated accelerated [correction of accelerated] radio-therapy (CHART) randomized trial in non-small-cell lung cancer. CHART Steering Committee. J Clin Oncol 1998, 16:3082–3093.

    PubMed  CAS  Google Scholar 

  60. Saunders MI, Rojas A, Lyn BE, et al.: Experience with dose escalation using CHARTWEL (continuous hyper-fractionated accelerated radiotherapy weekend less) in non-small-cell lung cancer. Br J Cancer 1998, 78:1323–1328.

    PubMed  CAS  Google Scholar 

  61. Mehta MP, Tannehill SP, Adak S, et al.: Phase II trial of hyperfractionated accelerated radiation therapy for nonresectable non-small-cell lung cancer: results of Eastern Cooperative Oncology Group 4593. J Clin Oncol 1998, 16:3518–3523.

    PubMed  CAS  Google Scholar 

  62. Nguyen LN, Komaki R, Allen P, et al.: Effectiveness of accelerated radiotherapy for patients with inoperable non-small cell lung cancer (NSCLC) and borderline prognostic factors without distant metastasis: a retrospective review. Int J Radiat Oncol Biol Phys 1999, 44:1053–1056.

    Article  PubMed  CAS  Google Scholar 

  63. Hayman J, Martel M, Haken R, Lichter A: Dose escalation in non-small cell lung cancer using conformal 3-dimensional radiation therapy: update of a phase I trial. Proc ASCO 1999, 18:1772–1799.

    Google Scholar 

  64. Armstrong J, Raben A, Zelefsky M, et al.: Promising survival with three-dimensional conformal radiation therapy for non-small cell lung cancer. Radiother Oncol 1997, 44:17–22.

    Article  PubMed  CAS  Google Scholar 

  65. Uitterhoeve AL, Belderbos JS, Koolen MG, et al.: Toxicity of high-dose radiotherapy combined with daily cisplatin in non-small cell lung cancer: results of the EORTC 08912 phase I/II study. European Organization for Research and Treatment of Cancer. Eur J Cancer 2000, 36:592–600.

    Article  PubMed  CAS  Google Scholar 

  66. Socinski MA, Rosenman JG, Schell MJ, et al.: Induction carboplatin/paclitaxel followed by concurrent carbo-platin/ paclitaxel and dose-escalating conformal thoracic radiation therapy in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified Phase I trial. Cancer 2000, 89:534–542.

    Article  PubMed  CAS  Google Scholar 

  67. Sause WT, Scott C, Taylor S, et al.: Radiation Therapy Oncology Group (RTOG) 88–08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 1995, 87:198–205.

    Article  PubMed  CAS  Google Scholar 

  68. Sause W, Kolesar P, Taylor SI, et al.: Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 2000, 117:358–364. A large intergroup trial that compared chemoradiation to hyperfractionated radiation.

    Article  PubMed  CAS  Google Scholar 

  69. Komaki R, Scott CB, Sause WT, et al.: Induction cisplatin/ vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer: failure patterns by cell type in RTOG 88–08/ECOG 4588. Radiation Therapy Oncology Group. Eastern Cooperative Oncology Group. Int J Radiat Oncol Biol Phys 1997, 39:537–544.

    Article  PubMed  CAS  Google Scholar 

  70. Brattstrom D, Bergqvist M, Hesselius P, et al.: Different fraction schedules and combinations with chemother-apy in radiation treatment of non-small cell lung cancer. Anticancer Res 2000, 20:2087–2090.

    PubMed  CAS  Google Scholar 

  71. Segawa Y, Ueoka H, Kiura K, et al.: A phase II study of cisplatin and 5-fluorouracil with concurrent hyper-fractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group. Br J Cancer 2000, 82:104–111.

    Article  PubMed  CAS  Google Scholar 

  72. Lee JS, Scott C, Komaki R, et al.: Concurrent chemo-radiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: radiation therapy oncology group protocol 91–06. J Clin Oncol 1996, 14:1055–1064.

    PubMed  CAS  Google Scholar 

  73. Byhardt RW, Scott CB, Ettinger DS, et al.: Concurrent hyperfractionated irradiation and chemotherapy for unresectable nonsmall cell lung cancer. Results of Radiation Therapy Oncology Group 90–15. Cancer 1995, 75:2337–2344.

    Article  PubMed  CAS  Google Scholar 

  74. Komaki R, Scott C, Lee JS, et al.: Impact of adding concurrent chemotherapy to hyperfractionated radiotherapy for locally advanced non-small cell lung cancer (NSCLC): comparison of RTOG 83–11 and RTOG 91–06. Am J Clin Oncol 1997, 20:435–440.

    Article  PubMed  CAS  Google Scholar 

  75. Oral EN, Bavbek S, Kizir A, et al.: Preliminary analysis of a phase II study of Paclitaxel and CHART in locally advanced non-small cell lung cancer. Lung Cancer 1999, 25:191–198.

    Article  PubMed  CAS  Google Scholar 

  76. Choy H, Devore RF 3rd, Hande KR, et al.: A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a Vanderbilt Cancer Center Affiliate Network Study). Int J Radiat Oncol Biol Phys 2000, 47:931–937.

    Article  PubMed  CAS  Google Scholar 

  77. Komaki R, Scott C, Ettinger D, et al.: Randomized study of chemotherapy/radiation therapy combinations for favorable patients with locally advanced inoperable nonsmall cell lung cancer: Radiation Therapy Oncol-ogy Group (RTOG) 92–04. Int J Radiat Oncol Biol Phys 1997, 38:149–155.

    Article  PubMed  CAS  Google Scholar 

  78. Komaki R, Seiferheld W, Ettinger D, et al.: Randomized chemoradiation for patients with locally advanced inoperable non-small cell lung cancer: long-term follow-up of RTOG 92–04. Ninth World Conference on Lung Cancer 2000, 29:304.

    Google Scholar 

  79. Byhardt RW, Scott C, Sause WT, et al.: Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 1998, 42:469–478.

    Article  PubMed  CAS  Google Scholar 

  80. Movsas B, Scott C, Sause W, et al.: The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): a quality-adjusted survival analysis of radiation therapy oncology group (RTOG) chemo-radiation studies. Int J Radiat Oncol Biol Phys 1999, 45:1143–1149.

    Article  PubMed  CAS  Google Scholar 

  81. Curran W, Scott C, Langer C, et al.: Phase III comparison of sequential versus concurrent chemoradiation for patients with unresected stage III non-small cell lung cancer: report of Radiation Therapy Oncology Group 9410. Ninth World Conference on Lung Cancer 2000, 29:303.

    Google Scholar 

  82. Jeremic B, Shibamoto Y, Acimovic L, Djuric L: Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J Clin Oncol 1995, 13:452–458.

    PubMed  CAS  Google Scholar 

  83. Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S:Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study. J Clin Oncol 1996, 14:1065–1070.

    PubMed  CAS  Google Scholar 

  84. Ball D, Bishop J, Smith J, et al.: A randomised phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer: final report of an Australian multi-centre trial. Radiother Oncol 1999, 52:129–136.

    Article  PubMed  CAS  Google Scholar 

  85. Baumann M: Accelerated radiation therapy in non-small cell lung cancer. Radiother Oncol 1999, 52:97–99.

    Article  PubMed  CAS  Google Scholar 

  86. von Pawel J, von Roemeling R, Gatzemeier U, et al.:Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: a report of the international CATAPULT I study group. Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors. J Clin Oncol 2000, 18:1351–1359.

    Google Scholar 

  87. Swisher SG, Roth JA, Nemunaitis J, et al.: Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst 1999, 91:763–771.

    Article  PubMed  CAS  Google Scholar 

  88. You L, Yang CT, Jablons DM: ONYX-015 works synergistically with chemotherapy in lung cancer cell lines and primary cultures freshly made from lung cancer patients. Cancer Res 2000, 60:1009–1013.

    PubMed  CAS  Google Scholar 

  89. Khuri FR, Nemunaitis J, Ganly I, et al.: A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluo-rouracil in patients with recurrent head and neck cancer. Nat Med 2000, 6:879–885.

    Article  PubMed  CAS  Google Scholar 

  90. Rogulski KR, Freytag SO, Zhang K, et al.: In vivo anti-tumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy. Cancer Res 2000, 60:1193–1196.

    PubMed  CAS  Google Scholar 

  91. Wojtowicz-Praga S, Torri J, Johnson M, et al.: Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J Clin Oncol 1998, 16:2150–2156.

    PubMed  CAS  Google Scholar 

  92. Shalinsky DR, Brekken J, Zou H, et al.: Marked anti-angiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies. Clin Cancer Res 1999, 5:1905–1917.

    PubMed  CAS  Google Scholar 

  93. Ciardiello F, Caputo R, Bianco R, et al.: Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000, 6:2053–2063.

    PubMed  CAS  Google Scholar 

  94. Baselga J, Pfister D, Cooper MR, et al.: Phase I studies of anti-epidermal growth factor receptor chimeric anti-body C225 alone and in combination with cisplatin. J Clin Oncol 2000, 18:904–914.

    PubMed  CAS  Google Scholar 

  95. Milas L, Mason K, Hunter N, et al.: In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 2000, 6:701–708.

    PubMed  CAS  Google Scholar 

  96. Huang SM, Bock JM, Harari PM: Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999, 59:1935–1940.

    PubMed  CAS  Google Scholar 

  97. Planting AS, Catimel G, de Mulder PH, et al.: Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. EORTC Head and Neck Cooperative Group. Ann Oncol 1999, 10:693–700.

    Article  PubMed  CAS  Google Scholar 

  98. Buntzel J, Kuttner K, Frohlich D, Glatzel M: Selective cytoprotection with amifostine in concurrent radio-chemotherapy for head and neck cancer. Ann Oncol 1998, 9:505–509.

    Article  PubMed  CAS  Google Scholar 

  99. Brizel DM, Wasserman TH, Henke M, et al.: Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 2000, 18:3339–3345.

    PubMed  CAS  Google Scholar 

  100. Bourhis J, De Crevoisier R, Abdulkarim B, et al.:A randomized study of very accelerated radiotherapy with and without amifostine in head and neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2000, 46:1105–1108.

    Article  PubMed  CAS  Google Scholar 

  101. Trog D, Bank P, Wendt TG, et al.: Daily amifostine given concomitantly to chemoradiation in head and neck cancer. A pilot study. Strahlenther Onkol 1999, 175:444–449.

    Article  PubMed  CAS  Google Scholar 

  102. Werner-Wasik M, Friedland D, Axelrod R, et al.: Amifostine reduces severe esophagitis during concurrent chemotherapy with weekly paclitaxel and thoracic irradiation in patients with locally advanced non-small cell lung cancer. Proc ASCO 1999, 18:2267.

    Google Scholar 

  103. Roychowdhury D, Redmond K, Desai P, Looney S:A phase II trial of amifostine with paclitaxel, carbo-platin, and concurrent radiation therapy for unresectable non-small cell lung cancer. Proc ASCO 1999, 18:2011.

    Google Scholar 

  104. Koukourakis MI, Kyrias G, Kakolyris S, et al.: Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study. J Clin Oncol 2000, 18:2226–2233.

    PubMed  CAS  Google Scholar 

  105. Tannehill SP, Mehta MP, Larson M, et al.: Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small-cell lung cancer: results of a phase II trial. J Clin Oncol 1997, 15:2850–2857.

    PubMed  CAS  Google Scholar 

  106. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol 1997, 15:2996–3018.

  107. The Royal College of Radiologists’ Clinical Oncology Information Network: Guidelines on the non-surgical management of lung cancer.Clinical Oncology 1999, 11: S1–S54.

  108. Le Pechoux C, Arriagada R, Le Chevalier T, et al.:Concurrent cisplatin-vindesine and hyperfractionated thoracic radiotherapy in locally advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1996, 35:519–525.

    Article  PubMed  Google Scholar 

  109. Pignon T, Ruggieri S, Boutin C, et al.: Alternating chemotherapy and accelerated split-course irradiation in locally advanced nonsmall cell lung carcinoma. Cancer 1999, 85:2144–2150.

    Article  PubMed  CAS  Google Scholar 

  110. Kelly K, Hazuka M, Pan Z, et al.: A phase I study of daily carboplatin and simultaneous accelerated, hyperfractionated chest irradiation in patients with regionally inoperable non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1998, 40:559–567.

    Article  PubMed  CAS  Google Scholar 

  111. Baumohl J, Andrasina I, Valeriola D: Concomitant chemoradiotherapy in locally advanced non-small cell lung cancer using weekly taxol, daily carboplatin, and hyperfractionated radiotherapy. Proc ASCO 1999, 18:1915.

    Google Scholar 

  112. Kunikane H, Watanabe K, Kunitoh H, et al.: A phase II study of cisplatin and irinotecan as induction chemo-therapy and sequential accelerated hyperfractionated thoracic radiotherapy with daily low dose carboplatin in unresectable stage III non-small cell lung cancer. Proc ASCO 1999, 18:1979.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Hematology and Oncology, Department of Medicine, The University of Chicago, 5841 S. Maryland Avenue, 60637, Chicago, IL, USA

    Ezra E. W. Cohen MD & Everett E. Vokes MD

Authors
  1. Ezra E. W. Cohen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Everett E. Vokes MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cohen, E.E.W., Vokes, E.E. Locally advanced non-small cell lung cancer. Curr. Treat. Options in Oncol. 2, 27–42 (2001). https://doi.org/10.1007/s11864-001-0014-8

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-001-0014-8

Keywords

Search

Navigation